GlassScriptPhysician profile
Neel Bhalala
NPI 1992118624
$17,159.02
in general payments reported to CMS, 2019-2025
57 companies · $2,235 in 2025
The $2,235 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,953 · 2020: $1,682 · 2021: $2,226 · 2022: $2,259 · 2023: $2,805 · 2024: $2,998 · 2025: $2,235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,037.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,979.38 | 2020-2025 | Vraylar, Ubrelvy, Rinvoq |
| Astrazeneca Pharmaceuticals LP | $1,910.54 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,459.88 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,359.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $937.86 | 2019-2025 | Otezla, Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $776.82 | 2019-2024 | |
| Axsome Therapeutics, INC. | $733.68 | 2023-2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $688.05 | 2019-2025 | Jardiance, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $638.86 | 2019-2024 | Xifaxan |
| Pfizer INC. | $607.76 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $591.60 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $480.82 | 2019-2022 | |
| Glaxosmithkline, LLC. | $431.65 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Allergan, INC. | $402.03 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $311.80 | 2021-2025 | Ryaltris, Kloxxado, Mitigare |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neel Bhalala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.